See more : SAS AB (publ) (SAS.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Pluri Inc. (PLUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pluri Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KKR Group Finance Co. IX LLC 4. (KKRS) Income Statement Analysis – Financial Results
- PT Fortune Mate Indonesia Tbk (FMII.JK) Income Statement Analysis – Financial Results
- International Business Settlement Holdings Limited (0147.HK) Income Statement Analysis – Financial Results
- aReit Prop Limited (APO.JO) Income Statement Analysis – Financial Results
- Ircon International Limited (IRCON.BO) Income Statement Analysis – Financial Results
Pluri Inc. (PLUR)
About Pluri Inc.
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 326.00K | 287.00K | 234.00K | 0.00 | 23.00K | 54.00K | 50.00K | 0.00 | 2.85M | 379.00K | 379.00K | 679.00K | 716.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.00K | 9.00K | 41.59M | 50.62M | 1.57M | 2.00K | 2.00K | 2.18M | 100.00K | 13.00K | 11.00K | 20.00K | 21.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00K |
| Gross Profit | 322.00K | 278.00K | -41.36M | -50.62M | -1.55M | 52.00K | 48.00K | -2.18M | 2.75M | 366.00K | 368.00K | 659.00K | 695.00K | -1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.00K |
| Gross Profit Ratio | 98.77% | 96.86% | -17,674.79% | 0.00% | -6,726.09% | 96.30% | 96.00% | 0.00% | 96.49% | 96.57% | 97.10% | 97.05% | 97.07% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.45M | 15.75M | 24.38M | 30.07M | 21.58M | 26.43M | 22.63M | 21.09M | 19.58M | 19.17M | 19.54M | 17.23M | 9.18M | 6.63M | 4.30M | 3.14M | 4.39M | 2.55M | 1.30M | 1.79M | 1.22M | 79.87K | 0.00 |
| General & Administrative | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 112.96K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.66K | 0.00 |
| SG&A | 10.03M | 11.78M | 17.45M | 20.56M | 7.92M | 9.16M | 11.19M | 6.93M | 6.49M | 6.46M | 8.68M | 5.65M | 6.57M | 4.49M | 3.14M | 3.42M | 6.04M | 3.73M | 1.03M | 873.65K | 1.78M | 130.62K | 74.45K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -43.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 168.62K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.48M | 27.52M | 41.83M | 50.62M | 29.50M | 35.58M | 33.78M | 28.02M | 26.07M | 25.63M | 28.22M | 22.88M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Cost & Expenses | 22.48M | 27.53M | 41.83M | 50.62M | 29.50M | 35.59M | 33.78M | 28.02M | 26.17M | 25.65M | 28.23M | 22.90M | 15.75M | 11.11M | 7.44M | 6.56M | 10.43M | 6.28M | 2.33M | 2.83M | 3.00M | 210.49K | 74.45K |
| Interest Income | 1.31M | 1.08M | 581.00K | 492.00K | 384.00K | 385.00K | 276.00K | 122.00K | 149.00K | 112.00K | 246.00K | 266.00K | 575.00K | 236.00K | 2.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 866.00K | 843.00K | 887.00K | 78.00K | 196.00K | 29.00K | 937.00K | 0.00 | 100.00K | 37.00K | 36.00K | 29.00K | 12.00K | 13.00K | 31.00K | 8.00K | 0.00 | 23.02K | 0.00 | 0.00 | 0.00 | 0.00 | 3.45K |
| Depreciation & Amortization | 253.00K | 362.00K | 1.05M | 1.37M | 1.57M | 1.96M | 2.02M | 2.18M | 2.15M | 2.07M | 1.90M | 1.03M | 435.00K | 312.00K | 207.00K | 173.00K | 129.00K | 224.72K | 264.83K | 202.85K | 153.64K | 21.04K | 0.00 |
| EBITDA | -20.23M | -27.68M | -39.43M | -48.42M | -27.39M | -33.35M | -24.05M | -25.57M | -21.01M | -22.57M | -25.03M | -21.19M | -14.35M | -10.52M | -7.23M | -6.51M | -10.35M | -7.42M | -2.10M | -1.87M | -1.84M | 0.00 | -74.45K |
| EBITDA Ratio | -6,203.99% | -8,995.12% | -17,087.18% | 0.00% | -119,800.00% | -61,924.07% | -79,958.00% | 0.00% | -743.06% | -6,255.41% | -7,033.25% | -3,081.59% | -2,003.77% | 644.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.16M | -27.25M | -41.59M | -50.62M | -29.48M | -35.53M | -33.73M | -28.02M | -23.32M | -25.27M | -27.85M | -22.22M | -15.03M | -11.11M | -7.44M | -6.56M | -10.43M | -6.28M | -2.33M | -2.83M | -3.00M | -456.96K | -74.45K |
| Operating Income Ratio | -6,796.93% | -9,493.38% | -17,774.79% | 0.00% | -128,156.52% | -65,800.00% | -67,462.00% | 0.00% | -819.07% | -6,666.75% | -7,348.28% | -3,272.90% | -2,099.30% | 660.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 814.00K | -1.64M | 219.00K | 758.00K | 324.00K | 225.00K | 7.61M | 205.00K | 73.00K | 590.00K | 918.00K | 1.07M | 237.00K | 266.00K | -14.00K | -84.00K | -69.00K | -2.15M | -107.46K | 731.65K | 994.18K | 0.00 | 0.00 |
| Income Before Tax | -21.34M | -28.89M | -41.37M | -49.87M | -29.15M | -35.31M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -11.07M | -7.46M | -6.64M | 0.00 | -8.24M | 0.00 | -2.09M | 0.00 | 418.26K | 0.00 |
| Income Before Tax Ratio | -6,547.24% | -10,065.16% | -17,681.20% | 0.00% | -126,747.83% | -65,383.33% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 658.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 277.00K | -351.00K | 78.00K | 196.00K | -94.00K | 7.61M | -205.00K | -73.00K | -590.00K | -918.00K | 29.00K | 249.00K | -266.00K | 14.00K | 78.00K | 69.00K | 2.15M | 107.46K | -731.65K | -994.17K | 252.51K | 77.90K |
| Net Income | -20.89M | -28.32M | -41.02M | -49.94M | -29.35M | -35.21M | -26.13M | -27.81M | -23.25M | -24.68M | -26.93M | -21.16M | -14.79M | -10.85M | -7.45M | -6.64M | -10.50M | -8.43M | -2.44M | -2.10M | -2.01M | -463.00K | -77.90K |
| Net Income Ratio | -6,407.36% | -9,867.94% | -17,531.20% | 0.00% | -127,600.00% | -65,209.26% | -52,252.00% | 0.00% | -816.51% | -6,511.08% | -7,106.07% | -3,115.61% | -2,066.20% | 644.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| EPS Diluted | -3.99 | -6.18 | -10.19 | -14.21 | -12.90 | -22.84 | -19.74 | -25.45 | -23.38 | -28.09 | -33.92 | -30.50 | -26.88 | -27.82 | -35.06 | -50.07 | -130.77 | -467.52 | -639.99 | -822.71 | -120.34 | -27.71 | -4.66 |
| Weighted Avg Shares Out | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
| Weighted Avg Shares Out (Dil) | 5.24M | 4.58M | 4.02M | 3.51M | 2.27M | 1.54M | 1.32M | 1.09M | 994.35K | 878.55K | 793.93K | 693.52K | 550.40K | 389.99K | 212.56K | 132.54K | 80.28K | 18.03K | 3.81K | 2.55K | 16.71K | 16.71K | 16.71K |
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
Abony: “Pluri's cell expansion technology has extraordinary potential across a range of industries.” Abony: “Pluri's cell expansion technology has extraordinary potential across a range of industries.”
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
HAIFA, Israel, July 11, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced that it has signed a three...
Pluri to Present and Participate in Upcoming Conferences
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three upcoming conferences.
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short.
Best Penny Stocks to Buy as January Ends? 4 to Watch
Here are four penny stocks to add to your end of January watchlist The post Best Penny Stocks to Buy as January Ends? 4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks to Buy Right Now? 3 For Your List in January
Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein...
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.
Pluristem CEO Issues Shareholder Update
HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.
Source: https://incomestatements.info
Category: Stock Reports